Amoxicillin and Metronidazole in Association With Non-surgical Therapy in Aggressive Periodontitis Treatment
- Conditions
- Generalized Aggressive Periodontitis
- Interventions
- Drug: Placebos
- Registration Number
- NCT03933501
- Lead Sponsor
- University of Campinas, Brazil
- Brief Summary
This study is designed as a parallel, masked, randomized, placebo-controlled clinical trial to assess the clinical, microbiological, and immunological outcomes of scaling and root planning (SRP) or full-mouth ultrasonic debridement (FMUD) with AM (Amoxicillin + Metronidazole) for the treatment of Generalized Aggressive Periodontitis (GAgP).
- Detailed Description
Forty eight GAgP patients were divided into 4 groups: the SRP group (n = 12), which received SRP plus placebo, and the SRP+AM group (n = 12), which received SRP and 375mg amoxicillin plus 250 mg metronidazole for 7 days, the FMUD group (n = 12), which received FMUD plus placebo, and the FMUD+AM group (n = 12), which received FMUD and 375mg amoxicillin plus 250 mg metronidazole for 7 days. The following clinical outcomes were tested: plaque and bleeding on probing indices, pocket probing depth (PD), relative gingival margin position (GMP), and relative clinical attachment level (CAL). The total amount of Porphyromonas gingivalis (Pg), Aggregatibacter actinomycetemcomitans (Aa), Tannerella forsythia (Tf), and gingival crevicular fluid (GCF) concentration of interleukin (IL)-10 and IL-1b were also determined. All clinical, microbiological, and immunological parameters were assessed at baseline and at 3 and 6 months post-therapy. The ANOVA/Tukey test was used for statistical analysis (a = 5%).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
- diagnosis of GAgP;
- presence of 20 teeth;
- presence of teeth presenting PD>5 mm with bleeding on probing (BOP) and 2 teeth with PD>7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them);
- good general health;
- <35 years of age.
- were pregnant or lactating;
- were suffering from any other systemic diseases (e.g., cardiovascular, diabetes);
- received antimicrobials in the previous 3 months;
- were taking long-term anti-inflammatory drugs;
- received a course of periodontal treatment within the last 6 months;
- smoked
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description FMUD + AM amoxicillin and metronidazole One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days. SRP + AM amoxicillin and metronidazole Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days. FMUD Placebos One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days. SRP Placebos Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
- Primary Outcome Measures
Name Time Method Change of the baseline relative clinical attachment level at 6 months Baseline, 3 months and 6 months distance from the bottom of the pocket to the stent margin.
- Secondary Outcome Measures
Name Time Method Change of the baseline probing depth at 6 months Baseline, 3 months and 6 months Distance from the bottom of pocket to gingival margin;
Change of the baseline inflammatory markers levels in gingival crevicular fluid (pg/uL) at 6 months Baseline, 3 months and 6 months Concentration of IL-1β, IL-10 released in gingival crevicular fluid
Change in the microbial composition at 6 months Baseline, 3 months and 6 months Concentration of bacteria in the subgingival biofilm